Thursday, 18 April 2024

[the_ad_group id="2845"]

Business News

Stifel Nicolaus Remains a Buy on Black Diamond Therapeutics (BDTX) – TipRanks Financial Blog

Quipt Home Medical Corp (QIPT) Q4 Earnings Cheat Sheet – TipRanks Financial Blog

[the_ad id="21475"]


Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Black Diamond Therapeutics (BDTXResearch Report) yesterday and set a price target of $15.00. The company’s shares closed yesterday at $5.00.

Canino covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Kura Oncology, and Merus. According to TipRanks, Canino has an average return of 5.5% and a 46.90% success rate on recommended stocks.

Currently, the analyst consensus on Black Diamond Therapeutics is a Strong Buy with an average price target of $13.50, representing a 170.00% upside. In a report released on March 18, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.

Based on Black Diamond Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $334 thousand and a GAAP net loss of $19.41 million. In comparison, last year the company had a GAAP net loss of $21.08 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Black Diamond Therapeutics (BDTX) Company Description:

Black Diamond Therapeutics, Inc. engages in the biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms. The company was founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Click Here to Read the Full Original Article at TipRanks Financial Blog…


[the_ad id="21476"]